New advances in novel pharmacotherapeutic candidates for the treatment of metabolic dysfunction-associated steatohepatitis (MASH) between 2022 and 2024.

已完结 10 由 John 发布于 2025/9/28 13:32:20

DOI:10.1038/s41401-024-01466-7
文献类型：期刊论文
补充材料：只需要正文
文献链接：https://doi.org/10.1038/s41401-024-01466-7

Springer

Abstract：Metabolic dysfunction-associated steatotic liver disease (MASLD) covers a broad spectrum of profile from simple fatty liver, evolving to metabolic dysfunction-associated steatohepatitis (MAS

应助信息

求助已完结，文件已删除 如有需求请重新发布求助一键发布

感谢使用Book学术
本站所有文献仅供个人学习和参考，请勿将文件进行传播。共同遵守网站规定和相关知识产权规定。

上一个求助:其它数据库Naturally Fractured Carbonate Reservoir Characterization: A Case Study of a Mature High-Pour Point Oil Field in Hungary 下一个求助:其它数据库Precisely Bonded Fe─Cu Diatomic Sites with Nitrogen‐Bridged Coordination on Hollow C3N4 Spheres for Efficient C─N Coupling and Selective Photocatalytic Urea Synthesis